Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox 52-week study in transfusion-dependent beta-thalassemia with cardiac iron overload
2008-003230-22Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in beta thalassemia and hemosiderosis, sponsored by Novartis. Primary endpoint: Change in cardiac MRI T2* at 52 weeks. Started Jan 2009; status: completed.
02
Drugs
deferasirox
03
Conditions
beta thalassemiahemosiderosis
Beyond the preview
Go deeper on 2008-003230-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003230-22.